Valganciclovir
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical CenterSmall moleculePhase 4 / ApprovedActive
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 65/ 100
Competitive context
202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Weill Medical College of Cornell University | Phase 2 | BBB |
Chlorambucil Ascentage Pharma Group Inc. | Phase 4 | BBB |
Lisaftoclax Henan Cancer Hospital | Phase 3 | BBB |
Irinotecan IGM Biosciences, Inc. | Phase 2 | BBB |
Prednisone AstraZeneca | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Valganciclovir is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative · Phase 2
61 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →